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Abstract—Tumor volume modeling and control is a promising
way to design more efficient, personalized tumor treatment. This
requires a model of tumor growth dynamics, and a control
law to design the therapy. Tumor growth models are usually
nonlinear, while most control laws are linear, and the controllers
are designed for approximate linear models thus stable operation
is guaranteed only locally. We consider the application of a linear
state feedback for a nonlinear tumor growth model, and carry
out the qualitative analysis of the closed-loop model. We give
conditions for the control law parameters to have a globally
stable closed-loop system, and analyze the effect of the control law
parameters on the steady-state tumor volume and the maximal
drug injection.
Index Terms—tumor therapy, cancer therapy, tumor control
I. INTRODUCTION
Modeling tumor growth under the effect of some drugs is
motivated by the potential of optimizing tumor therapies. One
of the first models was the Hahnfeldt model [1], extended and
analyzed in [2], which describes antiangiogenic therapy, and
models the tumor volume and endothelial volume dynamics.
A bilinear model was given in [3], that was extended in [4]
to model tumor growth dynamics, tumor necrosis dynamics,
drug pharmacodynamics and pharmacokinetics. The model
parameters were identified based on experiments with an
angiogenic inhibitor in [4], but the model is formalized such
that it can be used to model the effect of many different drugs,
as we will discuss in Section II. We create the closed-loop
model by applying a linear state feedback control law, and
analyze the properties of the closed-loop system in Section
III.
Control of tumor models have been considered as a tool
to generate optimal therapeutic protocols. In [5], [6], control
of the Hahnfeld model was considered using linear control
techniques. In [7], the authors apply impulsive control of
chemotherapy, and carry out the analysis using Ljapunov
functions. Impulsive control of antiangiogenic therapy based
on the Hahnfeldt model is done in the recent work [8]. Benefits
of using discrete-time controller for therapy design based on
the Hahnfeld model were examined in [9]. Multiobjective
optimization is used in [10]. In [11], the control of combined
therapy is done with the consideration of time delays. Here, we
use the model from [4] with a linear control law, and analyse
the effect of the control law parameters on the qualitative
properties of the closed-loop system.
The qualitative analysis of a dynamical system means the
investigation of qualitative properties of the system, like sta-
bility of equilibrium points, local behavior of a system around
an equilibrium, determining of invariant manifolds etc. For
instance, qualitative analysis of the Moon-Rand system was
carried out in [12], while a gene model was analyzed using
these techniques in [13]. Here, we use qualitative analysis to
determine the behavior of the closed-loop system based on the
values of the model and control law parameters.
The analysis of the closed-loop model is carried out in
Section III, where the equilibrium points of the closed-loop
system are determined, and the stability (by which we mean
asymptotic stability) is analyzed by checking the eigenvalues
of the system matrix of the linearized model in the equilibrium.
All the computations are carried out symbolically using Math-
ematica [14]. We give conditions for the model parameters in
the form of inequalities that define when the tumor grows
without treatment and in which cases can the treatment be
effective. We give conditions for the parameters of the control
law that ensure that the closed-loop system has a globally
stable positive equilibrium point. In Section IV we show how
the value of the control law parameters effect the value of the
positive equilibrium of the system. The results can be used
both for the analysis and synthesis of control algorithms using
state feedback.
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II. TUMOR GROWTH MODEL
The tumor growth model used here was created to model
the effect of bevacizumab [4] and the parameters of the model
were identified based on mice experiments [15]. The tumor
growth model has three state variables: the volume of the
proliferating (living) tumor cells, the volume of the necrotic
(dead) tumor cells and the serum level of the applied drug.
The terms in the model can be explained using an analogy to
chemical reactions [16], [17], [18]. Suppose that the species
X1 represents the proliferating tumor volume, the species
X2 represents the necrotic tumor volume and the species
X3 represents the drug serum level. The formal chemical
equations of the model are:
• X1
a−−→ 2 X1 that defines that the tumor cells proliferate
(divide) with a tumor growth rate a. Using mass-action
kinetics, this equation results in the term x˙1 = ax1;
• X1
n−−→ X2 that defines the necrosis (death) of tumor
cells with necrosis rate n. Note that this necrosis is
independent of the treatment. Using mass-action kinetics,
this equation modifies the dynamics of the proliferating
and necrotic tumor volumes with the terms x˙1 = −nx1,
x˙2 = nx1;
• X3
c−−→ O that defines that there is an outflow of the
drug with a reaction rate coefficient c, i.e. the clearance
of the drug. Instead of the mass-action type, here we use
Michaelis–Menten kinetics in order to have a mixed-order
model for the pharmacokinetics, so this equation results
in the term x˙3 = −cx3/(KB +x3), where the parameter
KB is the Michaelis–Menten constant of the drug;
• X1 + X3
b−−→ X2 that defines that the effect of the drug
depends on the concentration of the drug and the tumor
volume, and the result is that proliferating tumor cells
become necrotic. The effect of the drug is considered
with Michaelis–Menten kinetics with Michaelis–Menten
constant ED50 (called the median effective dose [19])
resulting in the velocity term x1x3/(ED50 + x3). This
effect on the volumes is considered with reaction rate
coefficient b. The effect of this equation on the dynamics
of the proliferating and necrotic tumor volumes is ex-
pressed by the terms x˙1 = −bx1x3/(ED50 + x3) and
x˙2 = bx1x3/(ED50 + x3). Since these terms have the
dimension mm3/day, these terms can not be directly used
to modify the dynamics of the drug serum level, since
that has the dimension mg/(ml · day). Thus, we use the
constant κ with dimension mg/(ml · mm3) to define the
term x˙3 = −κbx1x3/(ED50+x3). Instead of κ, we will
use the constant bκ = κb in the remaining of the paper.
The combination of these terms give the differential equations
of the tumor growth model:
x˙1 = (a− n)x1 − b x1x3
ED50 + x3
(1)











































THE NOTATIONS, NAMES AND DIMENSIONS OF THE PARAMETERS OF THE
TUMOR GROWTH MODEL
where x1 is the time function of proliferating tumor volume
in mm3, x2 is the time function of necrotic tumor volume in
mm3, x3 is the time function of drug serum level in mg/ml,
u is the input that is the time function of drug injection rate
in mg/(ml ·day). The notations, names and dimensions of the
model parameters are summarized in Table I. The model is
formulated such that in a phsyiologically meaningful case all
the parameters are positive.
The output y of the system is the measured tumor volume
in mm3 that is the sum of the proliferating (x1) and necrotic
(x2) tumor volumes, i.e.
y = x1 + x2. (4)
The dynamics of the output is described by the differential
equation
y˙ = ax1 (5)
that is the sum of (1) and (2), thus the change of the measured
tumor volume depends only on the tumor growth rate constant
a and the actual volume of the proliferating tumor volume.
As a result by Volpert [20], also discussed in [18, pp. 153–
154], the dynamical system described by (1)–(3) is nonnega-
tive since it is kinetic. We will also use the positivity of the
system in the qualitative analysis in the following section.
A. Generalizations of the tumor growth model
The tumor growth model was validated using mice exper-
iments [15] with an angiogenic inhibitor called bevacizumab
[19], however this does not limit the application of the model
only for angiogenic inhibition. The model can be used to
describe the effect of any drug whose effect can be simplified
to the formal chemical equation X1 + X3
b−−→ X2, i.e.
if the drug and a living tumor cell meets, the result is a
dead tumor cell. Although various drugs applied in cancer
therapies may act throughout different pathways, the final
result can be expressed by this simple equation. As a result,
the tumor growth model can be used to model the effect of
any therapeutic drug.
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There are two important physiological phenomena that were
not considered in [4] due to the nature of angiogenic inhibition
that are not negligible when chemotherapeutic agents are
used. The first phenomenon is the washout of the necrotic
tumor cells, i.e. the decrease of necrotic tumor volume as
the patients body decomposes and removes these cells. This
phenomenon was not characteristic when angiogenic therapy
was applied [15], the tumor was composed of proliferating
and necrotic regions, however washout may be present if a
chemotherapeutic drug is applied [21].
The washout can be modeled with the chemical reaction
equivalent X2
w−−→ O, that results in the differential equation
x˙2 = −wx2, considering mass-action kinetics. Thus, in order
to incorporate the effect of washout, (2) should be modified
to




However, the necrotic tumor cell volume does not affect
the dynamics of the closed-loop system discussed in the
following subsection, so we will omit the necrotic tumor
volume dynamics in the qualitative analysis (i.e. the results
will be valid independent of washout).
The other important phenomenon is that the tumor cells
may become resistant to the drug. However, this resistance is
only temporary. This effect can be modeled by adding an extra
dynamics for the drug efficiency rate b as
b˙ = (b0 − b)− βbx3, (7)
where b0 is the maximal value of the drug efficiency, and β
characterizes the speed of the development of resistance. Since
this increases the dimension of the system, it complicates the
qualitative analysis, thus we will not use this extension in this
article, but we will considered it in future research.
B. The closed-loop system dynamics
The right-hand side of the differential equations (1)–(3)
does not depend on x2, thus we may omit the dynamics of
the necrotic tumor volume, and only use the dynamics of the
proliferating tumor volume (1) and the drug serum level (3)
in the following analysis.
In order to get a closed-loop system and eliminate the
control input u to be able to carry out the analysis of the
model, we use the state feedback
u = k1x1 − k3x3. (8)
The state feedback is a general control law used widely in
control theory (for its application in tumor control, see e.g.
[5], [6]). The signs in the control law are chosen such that for
positive k1 and k3 values the feedback is negative.
The dynamics of the closed-loop system is acquired after
substituting the control law into the tumor growth model, i.e.
the closed-loop system dynamics is governed by
x˙1 = (a− n)x1 − b x1x3
ED50 + x3
(9)




+k1x1 − k3x3. (10)
In the following section we analyze the equilibria of the
closed-loop system, and the stability of the equilibria, and
give conditions for the parameter values k1 and k3 that ensure
the existence of a positive equilibrium and stability of that
equilibrium.
III. QUALITATIVE ANALYSIS OF THE CLOSED-LOOP
TUMOR GROWTH MODEL
In this section we analyze the equilibrium points of the
system described by (9)–(10) and the stability of those equi-
librium points. In order to simplify the equations, we multiply
both equations by the term x3 + ED50 to eliminate some of
the rational terms and get
x˙1 = (a− n)x1(ED50 + x3)− bx1x3 (11)
x˙3 = −cx3(ED50 + x3)
KB + x3
− bκx1x3
+(k1x1 − k3x3)(ED50 + x3). (12)
Multiplication with x3+ED50 will result in an extra equilib-
rium x3 = −ED50, however this case is not valid physiologi-
cally due to the positivity of the parameters and the variables.
The system has three more equilibrium points that are the same
as the equilibrium points of the original system. The signs of
the real parts of the eigenvalues of the Jacobian of the system
at the equilibrium points are also unaffected by multiplication
by the positive term ED50+x3. The Jacobian of the modified








J11 = (ED50 + x3)(a− n− bx3
ED50 + x3
) (14)
J12 = (a− b− n)x1 (15)
J21 = ED50k1 − (bκ − k1)x3 (16)
J22 = −ED50k3 − bκx1 + k1x1
−2k3x3 − c(ED50KB + x3(2KB + x3))
(KB + x3)2
.(17)
A. Equilibrium # 1
In the first equilibrium point x∗1 = 0 mm
3 and x∗3 = 0
mg/ml. This equilibrium point describes the trivial case when
there is no (living) tumor and no drug. The eigenvalues of the
Jacobian (13) at this equilibrium point are
λ1 = ED50 (a− n) (18)
λ2 = −ED50 c+ k3KB
KB
. (19)
Since we suppose that the parameters of the model are positive,
and if we suppose that k3 > 0, we have that λ2 < 0.
This eigenvalue describes the dynamics of the drug clearance,
which, if considered as a subsystem independent of the tumor
volume dynamics, is stable, so the zero drug level is a stable
equilibrium. Note that if k3 could be negative (i.e. we would
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have positive feedback in the control law), then it could be
chosen such that λ2 > 0 resulting in increasing drug level.
The other eigenvalue is the difference of the tumor growth
rate and the necrosis rate. If this difference is negative, i.e.
the tumor grows slower than it dies, then the equilibrium is
stable, i.e. the tumor is self-healing, it is being absorbed, and
therapy is not required.
In the special, degenerate case if a = n, the tumor growth
dynamics is described by
x˙1 = −b x1x3
ED50 + x3
(20)
thus for the initial tumor volume x(0), the tumor volume at
time instant t is
















if the limit at the right-hand side exists. In that case, since
x3 ∈ C1([0,∞],R+0 ), we have that x∗1 ≤ x1(0), i.e. if there
is no drug in the patient, then the equilibrium remains x1(0),
but if there is some drug injected, then the equilibrium volume
decreases: greater drug dose results in smaller equilibrium.
In the case a > n, the tumor grows faster than it dies, and
λ1 > 0, thus this equilibrium is unstable. In what follows we
will suppose that a > n, thus the tumor is not self-healing
and therapy is required, but k3 > 0, which implies that the
dynamics of the drug is stable around the zero equilibrium.
Such an equilibrium point is called a saddle.
B. Equilibrium # 2
In the second equilibrium point x∗1 = 0 mm
3 and x∗3 =
−(c + k3KB)/k3 mg/ml. For positive parameter values and
positive k3, the equilibrium point for the drug level is neg-
ative, which is physiologically unfeasible, so we neglect this
equilibrium.
C. Equilibrium # 3
In the third equilibrium point, the drug serum level is
x∗3 = −ED50
a− n
a− b− n. (23)
If the tumor is not self-healing, i.e. a > n, then this value is
positive if and only if
a− n− b < 0, (24)
which is the condition that ensures that tumor volume can be
decreased using the drug, as it was shown in [4]. From now
on, we suppose that the parameters satisfy (24).






x1,n = bED50(a− n) (b(c+ k3KB)
−a(c+ k3(−ED50 +KB))
+(c− ED50k3 + k3KB)n) (26)
x1,d = (a− b− n)(abκ − bk1 − bκn) ·
·(a(ED50 −KB) + bKB
+(−ED50 +KB)n). (27)
Taking into account the previous conditions, this equilibrium















aED50 − aKB + bKB − ED50n+KBn.(31)
The symbolic expression for the eigenvalues of the Jacoban
in this equilibrium point contain more than 2000 terms after
simplification, thus analysis of this equilibrium point is not
possible this way even with the use of computer algebra
software. In order to overcome this problem, we utilize the
fact that the system is planar, thus the Jacobian is a 2 × 2
matrix. For a 2×2 matrix J, the eigenvalues can be expressed






In order to have eigenvalues with negative real parts (i.e. to
guarantee that the equilibrium point is stable) the parameters
should be chosen such that
Tr(J) < 0 (33)
Det(J) > 0. (34)
Using computer algebra software (e.g. Mathematica with Re-
duce command) one can verify the following. The determinant
of the Jacobian is positive if (28)–(29) hold, but negative if
(30)–(31) are true. Thus, if the parameters of the control law
are chosen to satisfy (30)–(31), the equilibrium is unstable. If
conditions (28)–(29) are true, then the trace of the Jacobian is





condition also holds for k3 with
ϕ = c(−a+ b+ n)2(a2bκ(ED50 −KB)
−b2k1KB + 2abκ(−ED50 +KB)n
+bκ(ED50 −KB)n2) (36)
ω = (a(ED50 −KB) + bKB
+(−ED50 +KB)n)2(a2bκ
+b2k1 − 2abκn+ bκn2). (37)
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In this case, the positive equilibrium is stable, otherwise it is
unstable.
Note that in this equilibrium J11 = 0, thus Tr(J) = J22 and
Det(J) = −J12J21, which further simplifies the expressions.
However, the expressions still contain many terms (but they
can be handled with Mathematica, i.e. the commands are
executed in a reasonable time), so we omit the intermediate
results here. We summarize our main result in the following
theorem.
Theorem 1. Consider the closed-loop tumor growth model
given by the differential equations (9)–(10). Suppose that the
parameters of the model are positive and they satisfy a−n > 0
and a − n − b < 0. If the parameters k1 and k3 are chosen
such that (28)–(29) or (30)–(31) are satisfied, then there exists
a positive equilibrium of the system. Moreover, if k1 satisfies
(28) and k3 satisfies (35), then this equilibrium is stable.
IV. DISCUSSION AND CONCLUSION
In the previous section we have analyzed the qualitative
properties of the closed-loop tumor control model with the
application of state feedback. The results of the analysis give
us symbolic tools to either check if the closed-loop system
is stable for a previously designed state feedback controller
even in the presence of parametric perturbations, or to design
a controller using (28) and (35) and the known values (or inter-
vals if there is parametric uncertainty) of the parameters. This
way, we can guarantee that the resulting closed-loop system
is stable (even in the presence of parametric uncertainties).
Stability is a crucial property of the closed-loop system,
however, the steady-state value of the tumor volume is also
important. The equilibrium value is affected by the parameters
of the model and the parameters of the control law as well.
It can be verified using computer algebra that if the positivity
conditions of the parameters, the conditions a − n > 0, a −
n − b < 0, (28) and (35) hold, then the numerator and the
denominator of (25) are positive (i.e. x1,n > 0 and x1,d > 0).
The numerator depends on k3, but does not depend on k1,
while the denominator depends on k1 and does not depend on
k3.
The derivative of the numerator of (25) with respect to k3
is
∂k3x1,n = bED50(a− n)(bKB − a(−ED50 +KB)
+(−ED50 +KB)n) (38)
that is always positive with the given conditions, thus increas-
ing k3 means increasing steady-state tumor volume. This is
physiologically feasible too, since increasing k3 means faster
depletion of the drug, thus the effect of the drug will be
smaller. Decreasing k3 would result in smaller steady-state
tumor volume, however, too small k3 (i.e. which violates (35))
would result in an unstable equilibrium point. As a conclusion,
k3 should be small enough to have small steady-state tumor
volume, but large enough to have stable operation.
Fig. 1. The tumor volume (up) and drug serum level (bottom) in the case
of a scenario when there is no positive equilibrium (i.e., a− n− b > 0, the
red curves) and in the case when there exists a positive equilibrium and it is
asymptotically stable (green curve)
The derivative of the denominator of (25) with respect to
k1 is
∂k1x1,d = b(−a+ b+ n)(a(ED50 −KB) + bKB
+(−ED50 +KB)n) (39)
that is always positive with the given conditions, so increasing
k1 results in decreasing steady-state tumor volume. This shows
that larger values of k1 are desirable, moreover, increasing the
value of k1 does not violate the conditions for the stable equi-
librium. However, considering the control law (8), increasing
k1 means increasing control input, thus larger doses of the
drug, which may be toxic. An upper bound for the maximal
value of the input can be given as
umax = max
x1,x3,k1,k3>0
k1x1 − k3x3 ≤ k1x1,max (40)
which can be used to set an optimal value of the parameter
k1, if the value of umax is known.
The closed-loop system has only two valid equilibrium
points, the first valid equilibrium is x1 = 0 mm3, the second
valid equilibrium point is given by (25). If a− n > 0, i.e. the
first equilibrium is not stable, but the drug is effective against
the tumor (i.e. a−n−b < 0), then if the control law parameters
are chosen to satisfy (28) and (35), the second equilibrium is
stable, and there are no other positive equilibrium points. As
a result, for any positive initial tumor volume, the trajectories
of the system converge to the stable positive equilibrium, thus
that equilibrium is globally stable.
The simulation results of the closed-loop system with
k1 = 1 and k3 = 1 with two different parameter sets are
shown in Figure 1. The first parameter set is from [4], i.e.,
the parameters were identified based on mice experiments
carried out using bevacizumab. The values of the parameters
are: a = 0.4579 1/day, b = 0.1685 1/day, c = 0.1825 1/day,
n = 0.1030 1/day, bκ = 1.0839 · 10−6 mg/(ml · mm3 · day),
x1(0) = 49.0497mm3, x2(0) = 0mm3, x3(0) = 0mg/ml,
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Fig. 2. The tumor volume (up) and drug serum level (bottom) in the case
of existence of an asymptotically stable positive equilibrium
KB = 0.4409mg/ml and ED50 = 50 · 10−6 mg/ml. In this
case, there is no positive equilibrium, since a − n − b =
0.1864 > 0. The simulation results for this parameter set are
shown by the red curves in Figure 1.
The second parameter set is a modified version of the first
one where the parameter values b and n are modified in order
to ensure that a − n − b < 0. The modified values are b =
0.2685 1/day, and n = 0.3030 1/day. In this case a − n −
b = −0.1136 < 0, thus there exists a positive equilibrium.
In order to have an asymptotically stable positive equilibrium
based on Theorem 1, the feedback gains should satisfy (28)
and (35). For the second parameter set, these bounds are k1 >
6.25·10−7and k3 > −0.4139. Since the gains are chosen to be
k1 = 1 and k3 = 1, the conditions of Theorem 1 are satisfied.
The simulation results are shown for 18 day in Figure 1 by the
green curves. The simulation is repeated for 60 days and the
results are shown separately from the unstable case in Figure 2.
The results show that there is a stable positive equilibrium, and
the trajectories converge to this equilibrium. The value of this
equilibrium based on (25) and (23) is x∗1 = 9.63 · 10−5 mm3,
x∗3 = 6.81 · 10−5 mg/ml that is verified by the simulation as
well.
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